Pharming Group's Joenja Approved In Japan As First Targeted Treatment For Activated PI3K Delta Syndrome In Patients Aged 4 Years And Older

Pharming Group's drug Joenja has been approved in Japan as the first targeted treatment for activated PI3K delta syndrome (APDS) in patients aged 4 years and older. This approval is based on positive Phase III data from both multinational and Japanese studies for patients aged 12 and older, as well as a pediatric study for children aged 4 to 11. This marks the first approval of Joenja for the younger age group with APDS.